Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Binge Eating Disorder - Overview
Binge Eating Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Binge Eating Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Binge Eating Disorder - Companies Involved in Therapeutics Development
Amygdala Neurosciences Inc
AWAKN Life Sciences Corp
Bioprojet SCR
Bright Minds Biosciences Inc
Chronos Therapeutics Ltd
Clearmind Medicine Inc
F. Hoffmann-La Roche Ltd
Omeros Corp
Otsuka Pharmaceutical Co Ltd
OXonium Therapeutics
Trigemi Inc
Tryp Therapeutics Inc
Yichang Renfu Pharmaceutical Co Ltd
Binge Eating Disorder - Drug Profiles
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMB-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BP-1.4979 - Drug Profile
Product Description
Mechanism Of Action
History of Events
centafadine SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMND-100 - Drug Profile
Product Description
Mechanism Of Action
CT-010018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
Product Description
Mechanism Of Action
ketamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
lisdexamphetamine dimesylate - Drug Profile
Product Description
Mechanism Of Action
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
oxytocin - Drug Profile
Product Description
Mechanism Of Action
History of Events
psilocybin - Drug Profile
Product Description
Mechanism Of Action
History of Events
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRP-8803 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Binge Eating Disorder - Dormant Projects
Binge Eating Disorder - Discontinued Products
Binge Eating Disorder - Product Development Milestones
Featured News & Press Releases
Jun 29, 2022: Tryp Therapeutics strengthens IP portfolio with provisiol patent application for binge eating disorder treatment
Jun 09, 2022: Tryp Therapeutics announces results of first patient dosed in its phase II clinical trial for the treatment of binge eating disorder
May 26, 2022: Awakn Life Sciences files Patent Cooperation Treaty (PCT) Application for the treatment of behavioral addictions
May 10, 2022: SciSparc and Clearmind Medicine collaboration yields new patent application for psychedelic combition treatment for binge behaviors
Apr 28, 2022: Tryp Therapeutics doses first patient in phase II psilocybin-assisted therapy clinical trial
Mar 23, 2022: Tryp Therapeutics initiates enrollment for binge eating disorder study in partnership with University of Florida
Jan 05, 2022: Awakn Life Sciences expands world’s first ketamine study beyond gambling disorder to include additiol behavioral addictions
Dec 23, 2021: Tryp Therapeutics announces advancement of phase 2a clinical trial in binge eating disorder
Dec 03, 2021: Tryp Therapeutics to present at the H.C. Wainwright Psychedelics Conference on December 6, 2021
Nov 18, 2021: Tryp Therapeutics provides update on clinical hold for phase 2a study for eating disorders
Sep 22, 2021: Bright Minds Biosciences provides scientific update
Mar 03, 2021: Bright Minds Biosciences (“BMB”) proprietary 5-HT2C agonists show significant reduction in binge eating
May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder
Oct 06, 2016: Study Finds New Approach to Block Binge Eating
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Binge Eating Disorder, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Binge Eating Disorder, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Binge Eating Disorder - Pipeline by Amygdala Neurosciences Inc, 2022
Binge Eating Disorder - Pipeline by AWAKN Life Sciences Corp, 2022
Binge Eating Disorder - Pipeline by Bioprojet SCR, 2022
Binge Eating Disorder - Pipeline by Bright Minds Biosciences Inc, 2022
Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, 2022
Binge Eating Disorder - Pipeline by Clearmind Medicine Inc, 2022
Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Binge Eating Disorder - Pipeline by Omeros Corp, 2022
Binge Eating Disorder - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Binge Eating Disorder - Pipeline by OXonium Therapeutics, 2022
Binge Eating Disorder - Pipeline by Trigemina Inc, 2022
Binge Eating Disorder - Pipeline by Tryp Therapeutics Inc, 2022
Binge Eating Disorder - Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2022
Binge Eating Disorder - Dormant Projects, 2022
Binge Eating Disorder - Discontinued Products, 2022